Effect of ligustrazine on preventing contrast-induced nephropathy in patients with unstable angina

Ziliang Ye; Haili Lu; Qiang Su; Xinhua Xian; Lang Li

doi:10.18632/oncotarget.21310

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Effect of ligustrazine on preventing contrast-induced nephropathy in patients with unstable angina

Ziliang Ye, Haili Lu, Qiang Su _, Xinhua Xian and Lang Li

PDF | HTML | How to cite

Oncotarget. 2017; 8:92366-92374. https://doi.org/10.18632/oncotarget.21310

Metrics: PDF 1441 views | HTML 1778 views | ?

Abstract

Ziliang Ye1,2, Haili Lu2, Qiang Su1, Xinhua Xian2 and Lang Li1

1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institute, Nanning, Guangxi, China

2Guangxi Medical University, Nanning, Guangxi, China

Correspondence to:

Qiang Su, email: [email protected]

Lang Li, email: [email protected]

Keywords: ligustrazine, contrast-induced nephropathy, unstable angina

Received: May 04, 2017 Accepted: August 23, 2017 Published: September 28, 2017

ABSTRACT

Objective: Our purpose was to assess the effect of ligustrazine in the prevention of contrast-induced nephropathy (CIN) in patients with unstable angina (UA).

Methods: 148 patients with UA undergoing coronary angiography and/or percutaneous coronary intervention (PCI) were selected for observation; the patients were divided into a control group (group A, n=74) and a ligustrazine group (group B, n=74). Group A was given routine treatment, while group B was given routine treatment combined with ligustrazine. Serum creatinine (Scr), cystatin C and glomerular filtration rate (eGFR) concentrations were measured before and 1 day, 2 days and 3 days after treatment, and the incidence of contrast-induced nephropathy (CIN) and major cardiovascular events (MACE) were observed in both groups.

Results: The Scr, Cystatin C and eGRF levels in group B were better than in group A after 1 day (OR: 2.64, 95% CI: 2.47-4.98; OR: 2.66, 95% CI: 2.62-5.77; OR: 4.02, 95% CI: 3.02-5.53, respectively), 2 days (OR: 3.58, 95% CI: 2.41-4.92; OR: 2.92, 95% CI: 2.83-5.02; OR: 3.28, 95% CI: 3.24-5.14, respectively) and 3 days of treatment (OR: 3.26, 95% CI: 2.17-4.35; OR: 2.85, 95% CI: 2.26-4.02; OR: 3.19, 95% CI: 2.53-4.34, respectively). The incidence of CIN (9.26% vs 16.67%) and MACE (7.41% vs 18.51%) of group B were significantly lower than in group A (P<0.05).

Conclusions: Our study suggests that ligustrazine can reduce CIN and MACE in patients with UA when undergoing coronary angiography and/or PCI.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21310

Publication Alerts

Research Papers:

Effect of ligustrazine on preventing contrast-induced nephropathy in patients with unstable angina

Abstract